Sugi Predict

Sugi Predict / Compounds / SCHEMBL223564

SCHEMBL223564

SCHEMBL223564

O=Cc1nc2ccccc2o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 1/20 0.56
▸ HDAC4 P56524 1/20 0.56
▸ HDAC1 Q13547 1/20 0.56
▸ HDAC7 Q8WUI4 1/20 0.56
▸ HDAC2 Q92769 1/20 0.56
▸ HDAC10 Q969S8 1/20 0.56
▸ HDAC11 Q96DB2 1/20 0.56
▸ HDAC8 Q9BY41 1/20 0.56
▸ HDAC6 Q9UBN7 1/20 0.56
▸ HDAC9 Q9UKV0 1/20 0.56
▸ HDAC5 Q9UQL6 1/20 0.56
▸ SNCA P37840 1/20 0.51
▸ ADAMTS5 Q9UNA0 1/20 0.49
▸ MAPT P10636 4/20 0.48
▸ TP53 P04637 3/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ LMNA P02545 2/20 0.48
▸ NPC1 O15118 6/20 0.48
▸ RAB9A P51151 6/20 0.48
▸ MEN1 O00255 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421503 0.83 SNCA (0.64) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6421501 0.83 SNCA (0.64) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7472170 0.81 SNCA (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7472176 0.81 SNCA (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6607138 0.81 MEN1 (0.63) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL8718548 0.81 HDAC3 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6607140 0.81 MEN1 (0.63) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL8718547 0.81 HDAC3 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
Benzoxazolinone SCHEMBL140087 0.80 HDAC3 (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2
Benzoxazolinone SCHEMBL31124589 0.80 HDAC3 (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115433203-A Amine fluorinated curcumenol derivative compound and application and preparation method thereof 华东理工大学 2022-12-06 — — CN claimed
US-9896452-B2 Substituted prolines/piperidines as orexin receptor antagonists EOLAS THERAPEUTICS, INC. (US) 2018-02-20 — — US claimed
CN-104093715-B 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives 埃科特莱茵药品有限公司 2017-04-26 — — CN claimed
US-20170101410-A1 SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS EOLAS THERAPEUTICS, INC. 2017-04-13 — — US claimed
US-9440982-B2 Substituted prolines/piperidines as orexin receptor antagonists EOLAS THERAPEUTICS, INC. (US) 2016-09-13 — — US claimed
CN-104768946-A Fused pyrimidines as inhibitors of the p97 complex CLEAVE BIOSCIENCES INC 2015-07-08 — — CN claimed
EP-2811997-A1 SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS Eolas Therapeutics Inc. (US) 2014-12-17 — — EP claimed
WO-2013119639-A1 SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS EOLAS THERAPEUTICS, INC. (US) 2013-08-15 — — WO claimed
CN-103169708-A Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS INC 2013-06-26 — — CN claimed
CN-102014917-A Use of 2, 4-pyrimidinediamines for the treatment of atherosclerosis RIGEL PHARMACEUTICALS INC 2011-04-13 — — CN claimed
CN-1625400-A 2, 4-pyrimidinediamine compounds and uses thereof RIGEL PHARMACEUTICALS INC (US) 2005-06-08 — — CN claimed
CN-1163495-C Pyridine compounds, their preparation method and pharmaceutical compositions contg them ɪά��ʵ���� 2004-08-25 — — CN claimed
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2004-07-22 — — US claimed
US-6710056-B2 PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. AJINOMOTO CO., INC. (JP) 2004-03-23 — — US claimed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 — — EP claimed
US-20030109547-A1 Amidinophenylpyruvic acid derivatives AJINOMOTO CO. INC (JP) 2003-06-12 — — US claimed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 — — WO claimed
EP-1236712-A1 AMIDINOPHENYLPYRUVIC ACID DERIVATIVE Ajinomoto Co., Inc. (JP) 2002-09-04 — — EP claimed
CN-1286255-A Pyridine compounds, their preparation method and pharmaceutical compositions contg them ADIR (FR) 2001-03-07 — — CN claimed
CN-1039904-C Herbicides RHONE POULENC AGRICULTURE (GB) 1998-09-23 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109547-A1 Amidinophenylpyruvic acid derivatives HABP2, F2, F7 HDAC3 1097/4885HDAC4 1268/4885HDAC1 1286/4885
US-20170101410-A1 SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OPRL1 HDAC3 482/4885HDAC4 398/4885HDAC1 326/4885
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE HDAC3 251/4885HDAC4 704/4885HDAC1 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.